News &amp; Updates

Individuals with chronic obstructive pulmonary disease (COPD) appear to have poor balance and slower gait speed in the presence of pain, according to a study.

Pain linked to balance, gait issues in COPD

IBD patients who undergo coronary intervention at increased risk of MACE

Patients with inflammatory bowel disease (IBD) have a higher likelihood of experiencing major adverse cardiovascular events (MACE) after coronary interventions, according to a study.

IBD patients who undergo coronary intervention at increased risk of MACE

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

First-line treatment with the combination of fulzerasib and cetuximab appears to induce deep and durable responses in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring KRAS G12C mutation, in addition to having a favourable safety profile, according to the results of the phase II, open-label, single-arm KROCUS trial.

KRAS-mutant advanced NSCLC responds to fulzerasib–cetuximab combo

07 May 2025

HCQ improves platelet counts in children with chronic ITP

Treatment with hydroxychloroquine (HCQ) results in higher platelet counts in children with chronic immune thrombocytopenia (ITP), a study has shown. In addition, its efficacy is not associated with the baseline antinuclear antibody (ANA) level.

HCQ improves platelet counts in children with chronic ITP

Anticholinergic burden promotes poor cognition in psychosis patients

Anticholinergic burden appears to worsen cognitive functioning among patients with psychosis, but reducing the use of anticholinergic medication helps improve cognition, suggests a study.

Anticholinergic burden promotes poor cognition in psychosis patients

Baricitinib, abrocitinib show promise in treatment of lichen sclerosus

Among Janus kinase (JAK) inhibitors, baricitinib and abrocitinib demonstrate the most potential in improving the clinical symptoms of genital lichen sclerosus (LS), as shown in single-arm trials.

Baricitinib, abrocitinib show promise in treatment of lichen sclerosus

Add-on bireociclib promising for HR+/HER2- ABC following ET failure

In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).

Add-on bireociclib promising for HR+/HER2- ABC following ET failure

07 May 2025

Inebilizumab helps prevent flare-ups in IgG4-related disease

CD19-targeted B-cell depletion with inebilizumab appears to reduce the risk of flares and increase the likelihood of flare-free complete remission at 1 year in patients with IgG4-related disease, according to the phase III MITIGATE trial.

Inebilizumab helps prevent flare-ups in IgG4-related disease

Pembrolizumab plus CCRT improves survival in locally advanced cervical cancer

Adding pembrolizumab to concurrent chemoradiotherapy (CCRT) improves progression-free survival (PFS) and overall survival (OS) in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the second interim analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at SGO 2025.

Pembrolizumab plus CCRT improves survival in locally advanced cervical cancer

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors

A single dose of adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) over three RSV seasons in older adults aged ≥60 years, according to results of the phase III AReSVi-006 trial presented at ESCMID Global 2025.

Single-dose RSVPreF3 OA vaccine effective over 3 RSV seasons in seniors